Tirzepatide
Tirzepatide
Tirzepatide is like Semaglutide with a second lever — it activates two gut-hormone signals (GLP-1 and GIP) at once, which research suggests gives stronger effects on appetite, blood sugar, and body composition.
How Tirzepatide Works
A deeper look for the curious
For readers who want the full mechanism — feel free to skim.
Tirzepatide activates two gut-hormone signals at once — GLP-1 (fullness and insulin) and GIP (a complementary metabolic signal). Hitting both together produces larger effects on blood sugar, appetite, and body composition than either one alone. Like Semaglutide, it carries a fatty tail for once-weekly dosing.
Key Findings
What researchers have observed in studies
First-in-class dual incretin receptor agonist
Superior glycemic control vs. single-agonist compounds
Significant effects on body composition in research models
Novel biased agonism at the GIP receptor
GIP receptor + GLP-1 receptor (dual agonist)
39 amino acid peptide with C-20 fatty diacid
Amino acid chain
Commonly Used For
What scientists study this compound for
Weight management
Research shows larger average weight reductions than GLP-1-only compounds — currently the leading metabolic peptide in clinical trials.
Type 2 diabetes
Powerful improvements in HbA1c and insulin sensitivity in clinical studies.
Fatty liver (NAFLD)
Early research shows reductions in liver fat and markers of liver stress.
Sleep apnea
Weight-driven reductions in obstructive sleep apnea events in trial participants.
Product Features
Research Focus
HPLC Verified
High-performance liquid chromatography confirms compound purity for every batch we produce.
Mass Spec Confirmed
ESI-MS verifies molecular weight and structural identity match the target compound.
Certificate of Analysis
Complete analytical data including chromatograms and mass spectra available per batch.
Related Products
View allLaboratory use only. This product is sold for laboratory use and is not intended for human consumption or medical use.
Third-party verified. Typical purity ≥97%.